Burden of Disease in the Real-Life Setting of Patients with Atopic Dermatitis: Italian Data From the MEASURE-AD Study

introduction: atopic dermatitis (AD) is a chronic inflammatory skin disease that negatively impacts the quality of life and work productivity of patients.objectives: we sought to evaluate the real-world burden of AD patients in Italy. methods: this sub-analysis of the MEASURE-AD multicountry study conducted between december 2019-2020 included patients diagnosed with moderate-to-severe AD eligible for or receiving systemic therapy in the previous 6 months. during a single visit, physician and patient-reported questionnaires were used. results: a total of 118 adult patients were enrolled and 57.6% (N = 68) of patients had moderate-to-severe AD at the time of enrolment according to the eczema area and severity Index. sleep disorders interfered with daily function in the previous week in 58.5% (N = 69) of patients, pru-ritus was severe in 50% (N = 59) and 42.4% (N = 50) reported a flare lasting >7 days in the previous 6 months. according to the dermatology quality of Life Index, 37.3% (N = 44) of patients reported a severe impact of AD and approximately 10% had clinical depression/anxiety. current drug therapy was considered inadequate in controlling AD in 26.3% (N=31) of patients. work activity impairment was 38.6 +/- 31.7% and monthly AD-related expenses were 148.6 +/- 134.6 euros per patient. conclusions: this real-life study documents a high burden of disease in patients with moderate-severe AD in Italy.